Guest Columns

1. A Brief Overview Of Vaccine Purification Technologies And Analytical Tools 3/23/2023

   Downstream processing remains a major bottleneck for vaccine production, and the industry is racing to develop new purification technologies. Here's a snapshot of where we stand and of what needs to happen next to increase quality and yields.

2. How Can Life Sciences Navigate M&A In 2023? 3/21/2023

   As we close out the first quarter of 2023, let's take a look at how life sciences executives can conduct better M&A deals despite this unpredictable business environment.

3. The Global Market Landscape For Peptide Drug Conjugates 3/17/2023

   A peptide drug conjugate is a type of drug molecule that combines a peptide with another molecule, such as a small molecule drug or a protein, to create a new compound. New market research shares key factors and trends driving the market, as well as market segment insights.

4. A Short Guide On Transitioning From Monoclonal Antibody To AAV Separation Science 3/16/2023

   Separation scientists jumping from mAbs to AAV inherently have advantages, but familiarity can also present roadblocks. Here are a few tips on leveraging past experience with mAbs when developing AAV gene therapy products.

5. The Clinical Landscape Of ADCs In 2023: Diverse Technologies, Narrow Target 3/16/2023

   Antibody-drug conjugates (ADCs) are a type of targeted cancer therapy that combines the specificity of monoclonal antibodies with the potency of cytotoxic drugs. This article shares data surrounding the ADCs currently entering clinical trials, a look at failed ADC programs, and more.

6. Navigating Claim Scope For Functionally Claimed Biological Compounds After Amgen v. Sanofi 3/14/2023

   It can be difficult for broad biological compound claims to meet the two requirements in patent law that are used to “police” claim scope: the enablement requirement and the written description requirement. This article discusses the future of these types of patent claims after two Federal Circuit cases, Amgen v. Sanofi and Juno v. Kite.

7. Best Practices For Cell Culture Media Fingerprinting 3/13/2023

   This three-tier approach to cell culture media fingerprinting helps you to define an alternative method that will allow verification of the quality of the medium as well as fingerprinting. It helps you to choose suitable methods for incoming ID testing based on raw material properties, goals of media characterization, and the resources available. 

8. Add Efficiency From Development To Validation With Design Of Experiments 3/10/2023

   A statistically-based design of experiments shortens development timelines while reducing product development and validation costs. This works by shrinking the total number of experiments required to evaluate parameters while strengthening analysis.

9. Dispelling 4 Common Myths Of Data Quality Governance 3/9/2023

   Achieving robust data quality governance doesn't need to be an unwieldy prospect. Here, we dispel the four common myths of data quality governance and share the three phases of a good data quality governance program.

10. Tackling Safety Issues Of Adjuvanted Vaccines 3/8/2023

    An adjuvant is a substance added to some vaccines to enhance the immune response and/or to reduce the number of doses required to achieve a protective effect. This article discusses the emerging use of adjuvants and assessing safety issues.